| Helena EdlundPharmacokinetic/pharmacodynamic-guided optimisation of monoclonal antibody therapy in special populations |
---|
| | voorkant | achterkant |
| |
---|
ISBN: | 978-3-8440-5764-5 |
---|
Reeks: | Pharmazie |
---|
Trefwoorden: | monoclonal antibodies; infliximab; Crohn's disease; clinical pharmacy; mAbs; PK/PD processes of mAbs; anti-drug antibodies |
---|
Soort publicatie: | Dissertatie |
---|
Taal: | Engels |
---|
Pagina's: | 210 pagina's |
---|
Gewicht: | 278 g |
---|
Formaat: | 21 x 14,8 cm |
---|
Bindung: | Softcover |
---|
Prijs: | 49,80 € / 62,30 SFr |
---|
Verschijningsdatum: | Maart 2018 |
---|
Kopen: | |
---|
Aanbevelen: | Wilt u dit boek aanbevelen? |
---|
Recensie-exemplaar | Bestelling van een recensie-exemplaar. |
---|
Verlinking | Wilt u een link hebben van uw publicatie met onze online catalogus? Klik hier. |
---|
Samenvatting | Monoclonal antibodies constitute a therapeutically and economically important drug class, evident by the growing number on the market and in drug development. Still, sub-optimal use of monoclonal antibodies can result in loss of response or adverse events. In this thesis, pharmacometric modelling and simulation methodologies were applied to contribute to the pharmacokinetic/pharmacodynamic understanding of monoclonal antibodies in two populations, namely children and patients with Crohn's disease. |
---|